Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    E1609
Show Display Options
Rank Status Study
1 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
2 Recruiting Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: medical chart review
3 Recruiting Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly;   Drug: Placebo
4 Completed
Has Results
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2
5 Completed
Has Results
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: KW-2478;   Drug: Bortezomib
6 Completed Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Conditions: Leukemia;   Lymphoma;   Precancerous Condition;   Small Intestine Cancer
Interventions: Drug: arginine butyrate;   Drug: ganciclovir
7 Completed
Has Results
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149;   Drug: NVA237;   Drug: tiotropium;   Drug: Salbutamol/albuterol
8 Completed Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Conditions: Drug/Agent Toxicity by Tissue/Organ;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Oral Complications;   Radiation Toxicity
Interventions: Biological: filgrastim;   Biological: palifermin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: ifosfamide;   Procedure: quality-of-life assessment;   Radiation: radiation therapy
9 Recruiting A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Condition: Advanced Cutaneous Melanoma
Intervention:

Indicates status has not been verified in more than two years